Summary

Decades of clinical research relied on an exclusively male baseline, creating life-threatening blind spots in modern healthcare. Lisa Marceau reveals how moving from episodic doctor visits to continuous, personalized data ownership is the only way to dismantle systemic bias and prevent misdiagnoses. Closing this gap isn't just about equity; it's a biological necessity for survival.

Key Topics

• The 1977 FDA Research Ban: A regulatory guideline that prohibited women of childbearing age from participating in early-stage clinical trials. It created a multi-decade void in pharmacological data, meaning most modern drugs were never originally tested for efficacy or side effects in women.
• Episodic vs. Longitudinal Healthcare: The shift from treating health as a series of isolated events (doctor visits when symptoms appear) to a continuous stream of data tracking. This matters because it allows for the identification of trends and early risk factors that are invisible during a single 15-minute appointment.
• AI as Infrastructure: The philosophy that artificial intelligence is a foundational tool for efficiency and scaling, not the product itself. In healthcare, this means using AI to automate the 'lower risk' cases and administrative tasks so human clinicians can focus on high-complexity patient care.
• Microvascular vs. Macrovascular Disease: A biological distinction in how heart disease manifests; women often have microvascular issues in smaller arteries while men have macrovascular issues in larger ones. This matters because current diagnostic tools and 'standard' symptoms (chest pain) are designed for macrovascular disease, causing women's symptoms to be dismissed.

Key Takeaways

• Review your wearable health data for 'resting heart rate' and 'sleep variability' trends over the last 6 months.
• Audit your organization's health benefits to check for gender-specific diagnostic support.
• Ask your doctor specifically about microvascular disease symptoms during your next physical.